These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24312888)

  • 1. Feasibility study of clinical trial for breast cancer and lung cancer at Indian sites.
    Mehta VM; Bhatt AD
    Perspect Clin Res; 2013 Oct; 4(4):211-4. PubMed ID: 24312888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons why patients fail screening in Indian breast cancer trials.
    Mahajan P; Kulkarni A; Narayanswamy S; Dalal J; Halbe V; Patkar S; Bhatt A
    Perspect Clin Res; 2015; 6(4):190-3. PubMed ID: 26623389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy of a multistrain probiotic supplementation for prevention of neonatal sepsis in 0-2-month-old low birth weight infants in India-the "ProSPoNS" Study protocol for a phase III, multicentric, randomized, double-blind, placebo-controlled trial.
    Sinha AP; Gupta SS; Poluru R; Raut AV; Arora NK; Pandey RM; Sahu AR; Bethou A; Sazawal S; Parida S; Bavdekar A; Saili A; Gaind R; Kapil A; Garg BS; Maliye C; Jain M; Mahajan KS; Dhingra P; Pradhan KC; Kawade AS; Nangia S; Mukherjee A; Rasaily R; Sharma RS;
    Trials; 2021 Apr; 22(1):242. PubMed ID: 33794969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Good intentions and ICH-GCP: Trial conduct training needs to go beyond the ICH-GCP document and include the intention-to-treat principle.
    Browne LH; Graham PH
    Clin Trials; 2014 Dec; 11(6):629-34. PubMed ID: 25023199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three wound-dressing strategies to reduce surgical site infection after abdominal surgery: the Bluebelle feasibility study and pilot RCT.
    Reeves BC; Rooshenas L; Macefield RC; Woodward M; Welton NJ; Waterhouse BR; Torrance AD; Strong S; Siassakos D; Seligman W; Rogers CA; Rickard L; Pullyblank A; Pope C; Pinkney TD; Pathak S; Owais A; O'Callaghan J; O'Brien S; Nepogodiev D; Nadi K; Murkin CE; Munder T; Milne T; Messenger D; McMullan CM; Mathers JM; Mason M; Marshall M; Lovegrove R; Longman RJ; Lloyd J; Lim J; Lee K; Korwar V; Hughes D; Hill G; Harris R; Hamdan M; Brown HG; Gooberman-Hill R; Glasbey J; Fryer C; Ellis L; Elliott D; Dumville JC; Draycott T; Donovan JL; Cotton D; Coast J; Clout M; Calvert MJ; Byrne BE; Brown OD; Blencowe NS; Bera KD; Bennett J; Bamford R; Bakhbakhi D; Atif M; Ashton K; Armstrong E; Andronis L; Ananthavarathan P; Blazeby JM
    Health Technol Assess; 2019 Aug; 23(39):1-166. PubMed ID: 31392958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carer administration of as-needed subcutaneous medication for breakthrough symptoms in people dying at home: the CARiAD feasibility RCT.
    Poolman M; Roberts J; Wright S; Hendry A; Goulden N; Holmes EA; Byrne A; Perkins P; Hoare Z; Nelson A; Hiscock J; Hughes D; O'Connor J; Foster B; Reymond L; Healy S; Lewis P; Wee B; Johnstone R; Roberts R; Parkinson A; Roberts S; Wilkinson C
    Health Technol Assess; 2020 May; 24(25):1-150. PubMed ID: 32484432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    JBI Libr Syst Rev; 2005; 3(6):1-33. PubMed ID: 27819973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trial Educator program - a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial.
    Kendall B; Städeli R; Schegg B; Olbrich M; Chen E; Harmelin-Kadouri R; Aurup P; Schwab T; Hildemann SK
    Clin Trials; 2012 Jun; 9(3):358-66. PubMed ID: 22426648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pragmatic randomized trial evaluating pre-operative aqueous antiseptic skin solution in open fractures (Aqueous-PREP): the feasibility of a cluster randomized crossover study.
    Sprague S; Guyatt P; Bzovsky S; Nguyen U; Bhandari M; Thabane L; Petrisor B; Johal HS; Leonard J; Dodds S; Mossuto F; O'Toole RV; Howe A; Demyanovich HK; Camara M; O'Hara NN; Slobogean GP;
    Pilot Feasibility Stud; 2021 Mar; 7(1):61. PubMed ID: 33648577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of clinical trials by Ethics Committees in Germany--results and a comparison of two surveys performed among members of the German Association of Research-Based Pharmaceutical Companies (vfa).
    Russ H; Busta S; Jost B; Bethke TD
    Ger Med Sci; 2015; 13():Doc02. PubMed ID: 25698912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Form of Breast Intraoperative Radiation Therapy With CT-Guided High-Dose-Rate Brachytherapy: Results of a Prospective Phase 1 Clinical Trial.
    Showalter SL; Petroni G; Trifiletti DM; Libby B; Schroen AT; Brenin DR; Dalal P; Smolkin M; Reardon KA; Showalter TN
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):46-54. PubMed ID: 27511846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eligibility criteria in randomized phase II and III adjuvant and neoadjuvant breast cancer trials: not a significant barrier to enrollment.
    Filion M; Forget G; Brochu O; Provencher L; Desbiens C; Doyle C; Poirier B; DuRocher M; Camden S; Lemieux J
    Clin Trials; 2012 Oct; 9(5):652-9. PubMed ID: 23060323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Geriatric Assessment for Older Patients with Non-small Cell Lung Cancer: Daily Practice of Centers Participating in the NVALT25-ELDAPT Trial.
    Driessen EJM; van Loon JGM; Maas HA; Dingemans AC; Janssen-Heijnen MLG
    Lung; 2018 Aug; 196(4):463-468. PubMed ID: 29651598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.
    Zon R; Meropol NJ; Catalano RB; Schilsky RL
    J Clin Oncol; 2008 May; 26(15):2562-7. PubMed ID: 18390967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Project management lessons learned from the multicentre CYCLE pilot randomized controlled trial.
    McCaskell DS; Molloy AJ; Childerhose L; Costigan FA; Reid JC; McCaughan M; Clarke F; Cook DJ; Rudkowski JC; Farley C; Karachi T; Rochwerg B; Newman A; Fox-Robichaud A; Herridge MS; Lo V; Feltracco D; Burns KE; Porteous R; Seely AJE; Ball IM; Seczek A; Kho ME
    Trials; 2019 Aug; 20(1):532. PubMed ID: 31455384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.